Pfizer generated free cash flow of $10.4 billion in the 12 months ending Sept. 30, 2025. During this period, the pharma giant ...
Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...
This week's dividend activity included increased payouts from Taiwan Semiconductor Manufacturing Limited (TSM) and Goldman ...
Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...
Both Ford and Pfizer have very attractive dividend yields.
Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...
A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years. Investors appear to be worried ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback